Literature DB >> 32918903

External Drainage Alone Versus External Drainage With Vitrectomy in Advanced Coats Disease.

Ahmet Yucel Ucgul1, Sengul Ozdek2, Mestan Ertop3, Hatice Tuba Atalay3.   

Abstract

PURPOSE: To evaluate the efficacy of transscleral drainage of subretinal fluid (TDSRF) with and without pars plana vitrectomy (PPV), which are performed as an adjunct to ablative therapies in advanced Coats disease.
DESIGN: Retrospective, comparative case series. PATIENT POPULATION: A total of 31 eyes from 31 consecutive patients with advanced Coats disease at an average age of 47.8 ± 34.2 (2-156) months at the time of the surgery, who underwent TDSRF alone or in combination with PPV.
METHODS: Main outcome measurements were LogMAR visual acuity values, anterior and posterior segment findings, need for further surgery, laser photocoagulation, and anti-vascular endothelial growth factor (anti-VEGF) treatment. Anatomical success was defined as the maintenance of retinal reattachment without any further surgery during follow-up.
RESULTS: Sixteen patients underwent TDSRF alone, and 15 patients underwent combined TDSRF and PPV. Mean follow-up time was 34.8 ± 32.9 months (6-128). Anatomical success rate of combined TDSRF and PPV was higher than that of TDSRF alone (93.8% vs 75%, respectively). The incidence of epiretinal membrane formation, number of laser photocoagulation procedures, and anti-VEGF treatments were statistically significantly higher in the group that underwent TDSRF alone than in those who had combined TDSRF and PPV in the long term. There was an improvement in vision in only 4 eyes (12.9%) (all >3 years old at presentation) during the follow-up.
CONCLUSIONS: Combined TDSRF and PPV appears to be more effective in controlling the disease than TDSRF alone, as an adjunct to ablative procedures for the treatment of advanced Coats disease. The need for additional treatment is much less with the addition of PPV.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32918903     DOI: 10.1016/j.ajo.2020.09.006

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  1 in total

1.  Experience with Intravitreal Ranibizumab as an Adjunct to Ablation Therapy in Eyes with Exudative Coats' Disease.

Authors:  Mohamed Nowara; Yousef A Fouad; Ihab Abdel Aziz; Ahmed M Habib; Mariam Al-Feky; Hisham Hassan
Journal:  Clin Ophthalmol       Date:  2021-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.